Product 0405

DRUG4 trials

Sponsors

Fougera Pharmaceuticals Inc.

Conditions

Atopic Dermatitis

Phase 2

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

CompletedNCT01232543

Fougera Pharmaceuticals Inc.Atopic Dermatitis

Start: 2010-11-30End: 2011-11-30Updated: 2012-04-11

Phase 3

Study to Determine the Pharmacokinetics of Product 0405

WithdrawnNCT02176577

Fougera Pharmaceuticals Inc.Atopic Dermatitis

Start: 2012-06-30End: 2013-05-31Updated: 2014-06-27

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

WithdrawnNCT02176551

Fougera Pharmaceuticals Inc.Atopic Dermatitis

Start: 2012-06-30End: 2013-05-31Updated: 2014-06-27

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

WithdrawnNCT02176538

Fougera Pharmaceuticals Inc.Atopic Dermatitis

Start: 2012-06-30End: 2013-05-31Updated: 2014-06-27